This study is testing different combinations of up to five oral medications – hydroxychloroquine, metformin, sirolimus, dasatinib, and nelfinavir – for people with advanced solid tumors or recurrent prostate cancer. The main goals are to find the safest dose of these drug combinations and to see how many patients experience disease control. This study is for adults aged 18 and older. For prostate cancer, you must have a PSA (prostate-specific antigen) of at least 0.1 ng/mL. The study is currently recruiting about 76 participants.

Study design

This is a Phase I/II study with an initial group of 18-30 patients to find the safest drug combinations, followed by a larger group to assess effectiveness. It uses a traditional 3+3 escalation design to test increasing components of the drug regimen.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Disease control will be measured at a minimum of 16 weeks after starting treatment. The maximum tolerated dose will be measured at a minimum of 3 months after starting treatment on each dose level.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.